Demerger Spin Off Value Unlock
Expected: CurrentHIGH confidence
What: A&P Spend: Mid-teens %
“And that was the whole case of separation which would have led to this business as a standalone growing much faster than what it was in the past.”
Sanofi Consumer Healthcare India Ltd: Stock Analysis & Fundamentals
Updated this weekSanofi Consumer Healthcare India Ltd (Pharma - MNC bulk Drugs) — fundamental analysis, earnings data, and key metrics. PE: 42.7. ROE: 71.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
Sanofi Consumer Healthcare India Ltd Key Facts
What's Happening
👔Promoter buying — stake up 10.9% this quarter
🌐FII stake decreased 2.3% this quarter
🏛️DII reducing — stake down 6.6%
Earnings Acceleration Triggers
1. Demerger Spin Off Value Unlock
CurrentHIGH
2. Market Share Gains
By 2026HIGH
3. New Product Or Brand Launch
OngoingMEDIUM
Key Risks
1. Uncertainty regarding the timeline and final structure of the national OTC polic
MEDIUM2. Potential impact of raw material costs on the bottom line
LOWSector-Specific Signals
Avil Volume RankNumber 1
Allegra Value RankNumber 3
A&P Spend as % of SalesMid-teensIncreased from low single digits
HCP Reach Expansion Target2X
Key Numbers
Current Price
₹4,685
Dividend Yield
1.60%
Market Cap
10.8K Cr
Valuation
N/AWhy Are Sanofi Consumer Healthcare India Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Apr 19, 2026
Market Share Gains
Expected: By 2026HIGH confidence
What: Direct Retail Coverage: 2X
“So, both on the HCP side, consumer side and the retail side, efforts have been increased to make sure that our access and our reach becomes much larger.”
New Product Or Brand Launch
Expected: OngoingMEDIUM confidence
What: Product Pipeline: Allegra D
“I think one case in point was the launch of Allegra D, which just happened last year, which was one of the unique formulations that you see in the India market.”
Tam Expansion Changing Consumption
Expected: OngoingMEDIUM confidence
What: Self-medication rate: 1 in 4 consumers
“Almost 1 in every 4 consumers are self-medicating today. 15% where they ask the pharmacist. And that's a landscape that's only going to increase.”
Regulatory Approval Or License Win
Expected: FutureMEDIUM confidence
What: OTC Policy: Pending
“I think the biggest unlock will be direct consumer communication, you know, the moment OTC comes in, and then that gives us the freedom to really, again, build the category.”
Domestic sales growth of 22%
HIGH confidence
What: Domestic sales growth of 22%
“If you see the quarter for domestic sales, it grew by 22%, and you remove the recall from there. Without recall, the growth is 11%.”
What Are the Key Risks for Sanofi Consumer Healthcare India Ltd?
Earnings deceleration risks from management commentary
Uncertainty regarding the timeline and final structure of the national OTC polic
MEDIUMTrigger: The policy is still 'in the works' and its absence currently constrains direct consumer communication for certain brands.
Management view: The company is using brand extensions (like Combiflam cream) that are already allowed to speak to consumers directly.
Monitor: regulatory
Potential impact of raw material costs on the bottom line
LOWTrigger: Management noted they are 'very mindful' of the bottom line while increasing A&P spends.
Management view: Maintaining a lean and efficient independent supply chain to manage overall costs.
Monitor: commodity
What Is Sanofi Consumer Healthcare India Ltd's Management Saying?
Key quotes from recent conference calls
“So, we plan to double our doctor reach face to face. ... from where we are, we plan to double the reach to HCPs. [Initiative: HCP Reach Expansion]”
“Increasing direct retail coverage. ... And, of course, increasing our direct coverage also by 2X. [Initiative: Direct Retail Coverage]”
“So, the ANP, again, really moving from a very low single digit to mid-teens. And that was the whole case of separation. [Initiative: A&P Spend Increase]”
“As you're aware, the OTC policy is still in the works. ... so as of now, it's still in the works. [Risk (regulatory): MEDIUM]”
What Did Sanofi Consumer Healthcare India Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹880 crore
YoY +21%
Why: Revenue growth was driven by a 21% increase in operations and a recovery in domestic sales which grew by 22% including the impact of product recalls.
Management highlighted that without the recall impact, domestic sales growth was 11%.
EBITDA
Not Disclosed
YoY +13%Margin 37%
Why: Operating profit increased by 13% as the company focused on reigniting profitable growth and managing a lean and efficient supply chain.
The 37% margin refers to Profit from Operations as a percentage of turnover.
PAT
Not Disclosed
YoY +33%
Why: PAT growth of 33% was achieved through improved business performance and the successful relaunch of products that had been previously recalled.
The company is focusing on a 'challenger mindset' to drive differentiated reward structures and accountability.
Other Highlights
• ROCE recorded at 62.5% for the period.
• Domestic sales grew by 22% including recall recovery.
• Direct retail coverage target set to increase by 2X.
What Sector Metrics Matter for Sanofi Consumer Healthcare India Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Avil Volume Rank
Number 1
Allegra Value Rank
Number 3
A&P Spend as % of Sales
Mid-teens
YoY Increased from low single digits
Why: Strategic shift to fund growth through brand equity post-demerger.
HCP Reach Expansion Target
2X
Why: Plan to double face-to-face reach to healthcare professionals in 2026.
Direct Retail Coverage Target
2X
Why: Initiative to increase direct store presence for better visibility and range selling.
Digital HCP Reach
50,000
Why: Scaling up engagement efforts through digital channels.
Medical Representative Team Size
350
Why: Current size of the field force post-separation.
Indian Population Vitamin D Deficiency
70%
Why: Market potential indicator for the DePURA brand.
Consumer Self-Medication Rate
25%
Why: Reflects the growing trend of self-care and self-choice in healthcare.
In-India Production Share
100%
Why: Ensures independence from global supply chains and better stock control.
What Is Sanofi Consumer Healthcare India Ltd's Management Guidance?
Forward-looking targets from management
Management Tone: BULLISH
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Other Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Sanofi Consumer Healthcare India Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Sanofi Consumer Healthcare India Ltd's latest quarterly results?
Sanofi Consumer Healthcare India Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +36.0%
- Revenue Growth YoY: +32.4%
- Operating Margin: 39.0%
What is Sanofi Consumer Healthcare India Ltd's current PE ratio?
Sanofi Consumer Healthcare India Ltd's current PE ratio is 42.7x.
- Current PE: 42.7x
- Market Cap: 10.8K Cr
- Dividend Yield: 1.60%
What is Sanofi Consumer Healthcare India Ltd's price-to-book ratio?
Sanofi Consumer Healthcare India Ltd's price-to-book ratio is 28.1x.
- Price-to-Book (P/B): 28.1x
- Book Value per Share: ₹167
- Current Price: ₹4685
Is Sanofi Consumer Healthcare India Ltd a fundamentally strong company?
Sanofi Consumer Healthcare India Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 90.0%
Is Sanofi Consumer Healthcare India Ltd debt free?
Sanofi Consumer Healthcare India Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹25 Cr
What is Sanofi Consumer Healthcare India Ltd's return on equity (ROE) and ROCE?
Sanofi Consumer Healthcare India Ltd's return ratios over recent years
- Dec 2024: ROCE 111.0%
- Dec 2025: ROCE 90.0%
Is Sanofi Consumer Healthcare India Ltd's cash flow positive?
Sanofi Consumer Healthcare India Ltd's operating cash flow is positive (Dec 2025).
- Cash from Operations (CFO): ₹175 Cr
- Free Cash Flow (FCF): ₹183 Cr
- CFO/PAT Ratio: 73% (adequate)
What is Sanofi Consumer Healthcare India Ltd's dividend yield?
Sanofi Consumer Healthcare India Ltd's current dividend yield is 1.60%.
- Dividend Yield: 1.60%
- Current Price: ₹4685
Who holds Sanofi Consumer Healthcare India Ltd shares — promoters, FII, DII?
Sanofi Consumer Healthcare India Ltd's shareholding pattern (Mar 2026)
- Promoters: 71.3%
- FII (Foreign): 2.8%
- DII (Domestic): 17.6%
- Public: 8.4%
Is promoter holding increasing or decreasing in Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 71.3% (Mar 2026)
- Previous Quarter: 71.3% (Dec 2025)
- Change: 0.00% (stable)
Is Sanofi Consumer Healthcare India Ltd a new momentum entry or an established outperformer?
Sanofi Consumer Healthcare India Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd has 6 key growth catalysts identified from recent earnings analysis
- Demerger Spin Off Value Unlock — The separation from Sanofi allows the consumer business to fund its own growth through brand equity rather than a pharma-led prescription model.
- Market Share Gains — Doubling direct retail coverage and HCP reach is intended to capture headroom in core categories like allergy and pain.
- New Product Or Brand Launch — The company is leveraging global R&D to launch unique formulations like Allegra D for congestion.
- Tam Expansion Changing Consumption — Increasing consumer self-care and online health searches are expanding the addressable market for consumer healthcare brands.
What are the key risks in Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd has 2 key risks worth monitoring
- [MEDIUM] Uncertainty regarding the timeline and final structure of the national OTC polic — The policy is still 'in the works' and its absence currently constrains direct consumer communication for certain brands.
- [LOW] Potential impact of raw material costs on the bottom line — Management noted they are 'very mindful' of the bottom line while increasing A&P spends.
What did Sanofi Consumer Healthcare India Ltd's management say in the latest earnings call?
In Q3 FY26, Sanofi Consumer Healthcare India Ltd's management highlighted
- "So, we plan to double our doctor reach face to face. ... from where we are, we plan to double the reach to HCPs. [Initiative: HCP Reach Expansion]"
- "Increasing direct retail coverage. ... And, of course, increasing our direct coverage also by 2X. [Initiative: Direct Retail Coverage]"
- "So, the ANP, again, really moving from a very low single digit to mid-teens. And that was the whole case of separation. [Initiative: A&P Spend Increa..."
What is Sanofi Consumer Healthcare India Ltd's management guidance for growth?
Sanofi Consumer Healthcare India Ltd's management has provided the following forward guidance
- Revenue outlook: Not Given
- Margin outlook: Not Given
- Management tone: bullish
What sector-specific metrics matter most for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd's most important sub-sector-specific KPIs from the latest concall
- Avil Volume Rank: Number 1
- Allegra Value Rank: Number 3
- A&P Spend as % of Sales: Mid-teens (YoY Increased from low single digits) — Strategic shift to fund growth through brand equity post-demerger.
- HCP Reach Expansion Target: 2X — Plan to double face-to-face reach to healthcare professionals in 2026.
- Direct Retail Coverage Target: 2X — Initiative to increase direct store presence for better visibility and range selling.
- Digital HCP Reach: 50,000 — Scaling up engagement efforts through digital channels.
Is Sanofi Consumer Healthcare India Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Sanofi Consumer Healthcare India Ltd may be worth studying
- Cash flow is positive — CFO ₹175 Cr
What is the investment thesis for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Demerger Spin Off Value Unlock
Risk Factors (Bear Case)
- Key risk: Uncertainty regarding the timeline and final structure of the national OTC polic
What is the future outlook for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd's forward outlook based on current data signals
- Key Catalyst: Demerger Spin Off Value Unlock
- Key Risk: Uncertainty regarding the timeline and final structure of the national OTC polic
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.